| Literature DB >> 27162528 |
Ji-Won Choi1, Hun-Young Yoon1, Soon-Wuk Jeong1.
Abstract
Medical records of 139 tumors from 114 dogs that underwent surgery from May 2010 through March 2015 were retrospectively reviewed. Among 114 dogs, females (64.9%) were significantly more common than males (35.1%) (p<0.05). Dogs aged 6 to 10 years were more presented than non-tumor patients, however, there was no significant difference. The mean age (±SD) was 10.3±3.0 years. Although we found no significant difference of breed predisposition, the most common breed was Maltese (19.3%), followed by Shih-Tzu (14.0%), and Yorkshire terrier (13.2%). Proportional morbidity ratios (PMRs) of mammary gland, oral cavity, and skin tumors were high in Poodles, Yorkshire terriers, and Golden retrievers, respectively. Mammary gland (36.0%) was the most common site, followed by skin and soft tissues (12.2%), oral cavity (10.8%), and digestive organs (8.6%), but there was no significant difference. The objectives of surgery were curative surgery (86.2%), biopsy (4.9%), and palliative surgery (6.5%). In this study, 123 of 139 tumors had histopathological diagnoses. Adenocarcinoma was the most common type (n=24), followed by adenoma (n=17), soft tissue sarcoma (n=13), benign mixed tumor (n=5), and others (n=64). Recurrence or suspected metastasis was identified in 26 dogs. Median survival times of malignant mammary gland tumors, skin and subcutaneous tumors, and splenic tumors were 1,563.0±1,201.7, 469, and 128 days, respectively.Entities:
Keywords: Dog; Surgical Outcome; Tumor
Year: 2016 PMID: 27162528 PMCID: PMC4853497 DOI: 10.4110/in.2016.16.2.116
Source DB: PubMed Journal: Immune Netw ISSN: 1598-2629 Impact factor: 6.303
The signalments of the patients with tumor
| Variables | Tumor patients | Non-tumor patients | ||
|---|---|---|---|---|
| Number | Percent (%) | Number | Percent (%) | |
| Age | ||||
| <2 years | 0 | 0 | 120 | 12.9 |
| 2~6 years | 5 | 4.4 | 125 | 13.5 |
| 6~10 years | 38 | 33.3 | 194 | 20.9 |
| 10~14 years | 54 | 47.4 | 351 | 37.8 |
| >14 years | 16 | 14.0 | 136 | 14.7 |
| Unknown | 1 | 0.9 | 2 | 0.2 |
| Sex | ||||
| Female* | 74 | 64.9 | 494 | 53.2 |
| Intact female | 47 | 41.2 | 271 | 29.2 |
| Spayed female | 27 | 23.7 | 223 | 24.0 |
| Male | 40 | 35.1 | 435 | 46.8 |
| Castrated male | 26 | 22.8 | 278 | 29.9 |
| Intact male | 14 | 12.3 | 157 | 16.9 |
| Breed | ||||
| Maltese | 22 | 19.3 | 147 | 15.8 |
| Shih-tzu | 15 | 13.2 | 131 | 14.1 |
| Yorkshire terrier | 16 | 14.0 | 81 | 8.7 |
| Cocker spaniel | 11 | 9.6 | 66 | 7.1 |
| Mongrel | 10 | 8.8 | 67 | 7.2 |
| Other breeds | 40 | 35.1 | 437 | 47.1 |
Differences for analysis are considered to be significany at *p<0.05.
Other breeds: Poodle, Schnauzer, Golden retriever, Alaskan malamute, Labrador retriever, Jindo, Doberman pinscher, American pitbull terrier, Beagle, Chihuahua, Collie, Dachshund, Flat coated retriever, Miniature pinsher, Pug, Setter, Siberian husky.
Figure 1The distribution of purebred and crossbred in the malignant tumor patients.
The histopathologic diagnosis of the patients with tumor
| Type of neoplasm | No. | % |
|---|---|---|
| Benign | 36.7 | |
| Adenoma | 17 | 33.3 |
| Epithelioma | 6 | 11.8 |
| Benign mixed tumor | 5 | 9.8 |
| Others | 23 | 45.1 |
| Subtotal | 51 | 100 |
| Malignant | 51.8 | |
| Adenocarcinoma | 24 | 33.4 |
| Soft tissue sarcoma | 13 | 18.1 |
| Mast cell tumor | 5 | 6.9 |
| Malignant melanoma | 5 | 6.9 |
| Osteosarcoma | 5 | 6.9 |
| Others | 20 | 27.8 |
| Subtotal | 72 | 100 |
| Not examined | 16 | 11.5 |
| Total | 139 | 100 |
Figure 2The site of tumor development in the male and female patients.
The histopathologic diagnosis classified by the sites of tumor development
| ICD-O | Site of tumor development | Benign | Percent (%) | Malignant | Percent (%) |
|---|---|---|---|---|---|
| 000-14 | Lip, Oral cavity, Pharynx | Peripheral odontogenic fibroma | 25 | Malignant melanoma | 41.7 |
| Acanthomatous ameloblastoma | 16.7 | Squamous cell carcinoma | 8.3 | ||
| Epulis | 8.3 | ||||
| 15-26 | Digestive organs | Perianal gland epithelioma | 20 | Gastric adenocarcinoma | 10 |
| Perianal sebaceous adenoma | 10 | Hepatocellular carcinoma | 10 | ||
| Cholangiocarcinoma | 10 | ||||
| Small intestinal adenocarcinoma | 10 | ||||
| Perianal sebaceous adenocarcinoma | 10 | ||||
| Apocrine gland adenocarcinoma of anal sac | 10 | ||||
| Extraskeletal osteosarcoma | 10 | ||||
| 30-39 | Respiratory system | Nasal transitional carcinoma | 20 | ||
| Lung adenosquamous carcinoma | 40 | ||||
| Lung Adenocarcinoma | 40 | ||||
| 51-58 | Female genital | Leimyoma | 20 | Uterine carcinoma | 20 |
| Organs | Fibroma | 20 | Ovarian adenocarcinoma | 20 | |
| Vaginal polyp | 20 | ||||
| 50 | Mammary gland | Simple adenoma | 27.3 | Adenocarcinoma | 34.1 |
| Complex adenoma | 2.3 | Ductal carcinoma | 2.3 | ||
| Benign mixed tumor | 11.3 | Squamous cell carcinoma | 2.3 | ||
| Ductal adenoma | 2.3 | Liposarcoma | 2.3 | ||
| Lipoma | 4.5 | Anaplastic sarcoma | 2.3 | ||
| Osteosarcoma | 2.3 | ||||
| Carcinosarcoma | 4.5 | ||||
| Intraductal complex carcinoma | 2.3 | ||||
| 60-63 | Male genital organs | Seminoma | 50 | Sertoli cell tumor | 50 |
| 64-68 | Urinary tract | Transitional cell carcinoma | 50 | ||
| Renal cell carcinoma | 50 | ||||
| 42 | Spleen | Hemangioma | 14.3 | Hemangiosarcoma | 42.8 |
| Fibrosarcoma | 28.6 | ||||
| Malignant fibrous histiocytoma | 14.3 | ||||
| 69-72 | Ocular system | Sebaceous gland adenoma | 20 | ||
| Meibomian gland epithelioma | 20 | ||||
| Squamous papilloma | 20 | ||||
| Meibomian gland adenoma | 20 | ||||
| Uveal melanocytoma | 20 | ||||
| 44, 18 | Skin, Subcutaneous, | Lipoma | 11.7 | Basal cell carcinoma | 5.9 |
| Connective tissue | Sebaceous epithelioma | 17.6 | Aural squamous cell carcinoma | 5.9 | |
| Collagen nevus | 5.9 | Ceruminous gland adenocarcinoma | 5.9 | ||
| Mast cell tumor (Stage 2) | 5.9 | Mast cell tumor (Stage 3) | 29.4 | ||
| Ceruminous gland adenoma | 5.9 | ||||
| Ear polyp | 5.9 | ||||
| 40-41 | Bone | Osteosarcoma | 60 | ||
| Fibrosarcoma | 20 | ||||
| 75.4 | Carotid body | Carotid body tumor | 100 | ||
| 47 | Peripheral nerves and autonomic system | Hemangiopericytoma | 100 | ||
| 45 | Mesothelioma | Mesothelioma | 100 | ||
| 48 | Retroperitoneum | Hemangiosarcoma | 100 | ||
| 49 | Other soft tissue sarcoma | Fibrosarcoma | 50 | ||
| Rhabdomyosarcoma | 50 | ||||
| 81-96 | Malignant neoplasms of lymphoid, hematopoietic and related tissue | Lymphoma | 100 |
ICD-O, International Classification of Diseases for Oncology.
The Proportional Morbidity Ratio of breeds in specific tumor site
| Breeds | Mammary gland tumor | Skin tumor | Oral cavity tumor |
|---|---|---|---|
| Maltese | 1.111 | 0.870 | 1.111 |
| Yorkshire Terrier | 0.617 | 0.403 | 2.572 |
| Shih-tzu | 0.521 | 0.906 | - |
| Cocker spaniel | 1.389 | 1.610 | - |
| Mongrel | 0.833 | 1.449 | 1.852 |
| Poodle | 2.315 | 0.604 | - |
| Alaskan malamute | 0.556 | - | - |
| Golden Retriever | - | 5.435 | - |
The recurrence or suspected metastasis of tumor in the patients
| Site of tumor development | Recurrence or suspected metastasis (%) |
|---|---|
| Alimentary tract tumor | 33 |
| Mammary gland tumor | 26.5 |
| Hematopoietic system tumor | 25 |
| Bone tumor | 20 |
The survival rates of 6, 9, 12 months and local recurrence or suspected metastasis rate according to the surgical margin
| Surgical margin | No. | 6 months survival rate (%) | 9 months survival rate (%) | 12 months survival rate (%) | Local recurrence or suspected metastasis rate (%) |
|---|---|---|---|---|---|
| Marginal | 3 | 100 | 100 | 100 | 67 |
| Wide | 11 | 72.7 | 63.6 | 45.5 | 45.5 |
| Radical | 7 | 50 | 50 | 33 | 67 |
The histopathologic diagnosis and site of tumors classified according to the surgical margin
| Surgical margin | Histopathologic diagnosis of tumors | ICD-O | Site of tumor |
|---|---|---|---|
| Marginal | Perianal sebaceous adenocarcinoma | 44.5 | Perianal |
| Fibrosarcoma | 40-41 | Bone | |
| Rhabdomyosarcoma | 49 | Thoracic wall | |
| Wide | Extraskeletal osteosarcoma | 17.1 | Small intestine |
| Malignant melanoma | 000-14 | Oral cavity | |
| Squamous cell carcinoma | 000-14 | Oral cavity | |
| Intraductal complex carcinoma | 50 | Mammary gland | |
| Adenocarcinoma | 50 | Mammary gland | |
| Ductal carcinoma | 50 | Mammary gland | |
| Radical | Hepatocellular carcinoma | 22 | Liver |
| Malignant fibrous histiocytoma | 42.2 | Spleen | |
| Hemangiosarcoma | 42.2 | Spleen | |
| Osteosarcoma | 40-41 | Bone | |
| Mammary gland adenocarcinoma | 50 | Mammary gland | |
| Mast cell tumor | 44 | Skin (Limb) |
ICD-O, International Classification of Diseases for Oncology.
Figure 3Survival curve of the malignant mammary tumor. OHE, Ovariohysterectomy.